Literature DB >> 15471823

Electromechanical properties of perfusion/metabolism mismatch: comparison of nonfluoroscopic electroanatomic mapping with 18F-FDG PET.

Senta Graf1, Mariann Gyöngyösi, Aliasghar Khorsand, Stephan G Nekolla, Christian Pirich, Kurt Kletter, Robert Dudczak, Dietmar Glogar, Gerold Porenta, Heinz Sochor.   

Abstract

UNLABELLED: The aim of this study was to compare nonfluoroscopic electroanatomic mapping (NOGA), SPECT perfusion imaging, and PET metabolic imaging for assessment of myocardial viability. In particular, we sought to elucidate differences of electromechanical properties between the perfusion/metabolism mismatch as an indicator of a potentially reversible ischemic injury and the perfusion/metabolism match indicating irreversibly damaged myocardial tissue.
METHODS: Twenty-one patients with coronary artery disease underwent NOGA mapping of endocardial unipolar voltage, cardiac 18F-FDG PET of glucose utilization, and resting 201Tl SPECT of myocardial perfusion.
RESULTS: Electrical activity was 10.8 +/- 4.6 mV (mean +/- SD) in normal myocardium and was unchanged in hypoperfused segments with maintained glucose metabolism (perfusion/metabolism mismatch), 9.3 +/- 3.4 mV (P = not significant). In contrast, hypoperfused segments with a perfusion/metabolism match and nonviable segments showed significantly lower voltage (6.9 +/- 3.1 mV, P < 0.0001 and 4.1 +/- 1.1 mV, P < 0.0001 vs. normal). In hypoperfused segments, metabolic activity was more closely related to endocardial voltage than was myocardial perfusion (201Tl vs. voltage: r = 0.38, SEE = 3.2, P < 0.001; 18F-FDG PET vs. voltage: r = 0.6, SEE = 2.8, P < 0.0001).
CONCLUSION: In hypoperfused myocardium, electrical activity by NOGA mapping is more closely related to PET metabolic activity than to SPECT myocardial perfusion. As NOGA mapping does not differentiate hypoperfused myocardium with enhanced glucose utilization from normal myocardium, results from NOGA mapping need to be correlated with results from perfusion imaging to identify hypoperfused, yet viable, myocardium and to stratify patients for revascularization procedures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471823

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Endoventricular electromechanical mapping-the diagnostic and therapeutic utility of the NOGA XP Cardiac Navigation System.

Authors:  Peter J Psaltis; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2008-12-10       Impact factor: 4.132

Review 2.  Intramyocardial navigation and mapping for stem cell delivery.

Authors:  Peter J Psaltis; Andrew C W Zannettino; Stan Gronthos; Stephen G Worthley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-23       Impact factor: 4.132

3.  Myocardial viability assessment: poor correlation between electromechanical cardiac mapping and positron emission tomography in severe coronary artery disease.

Authors:  P A van der Vleuten; E S Tan; R A Tio; F Zijlstra
Journal:  Neth Heart J       Date:  2005-09       Impact factor: 2.380

Review 4.  Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease.

Authors:  Mariann Gyöngyösi; Nabil Dib
Journal:  Nat Rev Cardiol       Date:  2011-05-17       Impact factor: 32.419

5.  X-ray fused with magnetic resonance imaging (XFM) to target endomyocardial injections: validation in a swine model of myocardial infarction.

Authors:  Ranil de Silva; Luis F Gutiérrez; Amish N Raval; Elliot R McVeigh; Cengizhan Ozturk; Robert J Lederman
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

6.  Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01

7.  Comparison of NOGA endocardial mapping and cardiac magnetic resonance imaging for determining infarct size and infarct transmurality for intramyocardial injection therapy using experimental data.

Authors:  Noemi Pavo; Andras Jakab; Maximilian Y Emmert; Georg Strebinger; Petra Wolint; Matthias Zimmermann; Hendrik Jan Ankersmit; Simon P Hoerstrup; Gerald Maurer; Mariann Gyöngyösi
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.